Management of irritable bowel syndrome

Internal Medicine

Volumn 43, Issue 5, 2004, Pages 353-359

  Torii, Akira ^a   Toda, Gotaro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT (3) receptor antagonist; 5 HT (4) receptor agonist; Brain gut interaction; Calcium polycarbophil; Functional gastrointestinal disorder

Indexed keywords

ALOSETRON; ANTALARMIN; ANTIDIARRHEAL AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; LAXATIVE; LIDOCAINE; LOPERAMIDE; MAGNESIUM SALT; NEOSTIGMINE; PAROXETINE; POLYCARBOPHIL CALCIUM; PREDNISOLONE; PROKINETIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DIET THERAPY; DIETARY FIBER; DOCTOR PATIENT RELATION; FEMALE; GENETIC POLYMORPHISM; HEALTH CARE COST; HUMAN; IRRITABLE COLON; LIFESTYLE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT EDUCATION; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SEX RATIO; STRESS ULCER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; DIET; FEMALE; HUMANS; INCIDENCE; IRRITABLE BOWEL SYNDROME; JAPAN; LIFE STYLE; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SEX DISTRIBUTION; SICKNESS IMPACT PROFILE; STEROIDS; TREATMENT OUTCOME;

EID: 3042660156     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.353     Document Type: Review

References (51)

1. Quigley EM. Current concepts of the irritable bowel syndrome. Scand J Gastroenterol Suppl 237: 1-8, 2003.
2. Drossman DA, Carozziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut 45 (suppl. II): 1-81, 1999.
3. Cash BD, Chey WD. Advances in the management of irritable bowel syndrome. Curr Gastroenterol Rep 5: 468-475, 2003.
4. Torii A, Tanaka T, Matsueda K. The prevalence of irritable bowel syndrome with questionnaires at some company in Japan (in Japanese). Pharma Medica 20: 162-175, 2002.
5. Hasler WL. The irritable bowel syndrome during pregnancy. Gastroenterol Clin North Am 32: 385-406, 2003.
6. Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 13: 371-384, 1999.
7. Locke GR. Natural history of irritable bowel syndrome and durability of the diagnosis. Rev Gastroenterol Disord 3 Suppl 3: S12-S17, 2003.
8. Ehlin AG, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut 52: 1117-1121, 2003.
9. Naliboff BD, Berman S, Chang L, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 124: 1738-1747, 2003.
10. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord Suppl 2: S3-S11, 2003.
11. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 120: 652-668, 2001.
12. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology 123: 1686-1701, 2002.
13. Heitkemper M, Jarrett M, Bond EF, Chang L. Impact of sex and gender on irritable bowel syndrome. Biol Res Nurs 5: 56-65, 2003.
14. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 98: 600-607, 2003.
15. Patel RP, Petitta A, Fogel R, Peterson E, Zarowitz BJ. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol 35: 14-20, 2002.
16. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51: 1037-1044, 1998.
17. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51: 1045-1053, 1998.
18. Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 98: 122-127, 2003.
19. Groll D, Vanner SJ, Depew WT, et al. The IBS-36: a new quality of life measure for irritable bowel syndrome. Am J Gastroenterol 97: 962-971, 2002.
20. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 24: 675-689, 2002.
21. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 94: 2912-2917, 1999.
22. Simren M, Mansson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 63: 108-115, 2001.
23. Dapoigny M, Stockbrugger RW, Azpiroz F, et al. Role of alimentation in irritable bowel syndrome. Digestion 67: 225-233, 2003.
24. Talley NJ, Howell S, Poulton R. The irritable bowel syndrome and psychiatric disorders in the community: is there a link? Am J Gastroenterol 6: 1072-1079, 2001.
25. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 124: 1662-1671, 2003.
26. Spiller RC. Infection as a cause of irritable bowel syndrome. Hosp Med 64: 270-274, 2003.
27. Parry SD, Stansfield R, Jelley D, et al. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study. Am J Gastroenterol 98: 1970-1975, 2003.
28. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 122: 1771-1777, 2002.
29. Fukudo S, Kanazawa M, Kano M, et al. Exaggerated motility of the descending colon with repetitive distension of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol 37 Suppl 14: 145-150, 2002.
30. Ringel Y, Drossman DA, Turkington TG, et al. Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse. Dig Dis Sci 48: 1774-1781, 2003.
31. Bonaz B, Baciu M, Papillon E, et al. Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am J Gastroenterol 97: 654-661, 2002.
32. Drossman DA, Ringel Y, Vogt BA, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 24: 754-761, 2003.
33. O'Sullivan M, O'Morain C. Food intolerance: Dietary treatments in functional bowel disorders. Curr Treat Options Gastroenterol 6: 339-345, 2003.
34. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125: 19-31, 2003.
35. Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 98: 2209-2218, 2003.
36. Creed F, Fernandes L, Guthrie E, et al; North of England IBS Research Group. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124: 303-317, 2003.
37. Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther 7: 87-92, 1993.
38. Caldarella MP, Serra J, Azpiroz F, Malagelada JR. Prokinetic effects in patients with intestinal gas retention. Gastroenterology 122: 1748-1755, 2002.
39. Verne GN, Robinson ME, Vase L, Price DD. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 105: 223-230, 2003.
40. Huerta C, Garcia Rodriguez LA, Wallander MA, Johansson S. Users of oral steroids are at a reduced risk of developing irritable bowel syndrome. Pharmacoepidemiol Drug Saf 12: 583-588, 2003.
41. Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 18: 77-84, 2003.
42. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 8: 159-166, 1994.
43. Gabry KE, Chrousos GP, Rice KC, et al. Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs. Mol Psychiatry 7: 474-483, 2002.
44. Shaath NM, Whorwell PJ. 5-HT and the treatment of irritable bowel syndrome: A clinical perspective. Drugs Today 37: 437-440, 2001.
45. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 98: 750-758, 2003.
46. Olden K, DeGarmo RG, Jhingran P, et al. Lotronex Investigator Team. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 97: 3139-3146, 2002.
47. Mayer EA, Berman S, Derbyshire SW, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 16: 1357-1366, 2002.
48. Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 4: 2089-2098, 2003.
49. Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol 98: 1117-1122, 2003.
50. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123: 425-432, 2002.
51. Rivkin A. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review. Clin Ther 25: 1952-1974, 2003.